West Pharmaceutical Services (WST) reported Q3 adjusted earnings Thursday of $1.85 per diluted share, down from $2.16 a year earlier.
Analysts polled by Capital IQ expected $1.49.
Revenue for the quarter ended Sept. 30 was $746.9 million, compared with $747.4 million a year earlier.
Analysts surveyed by Capital IQ expected $709.6 million.
The company increased its 2024 adjusted EPS guidance to now be between $6.55 and $6.75 from the prior outlook of $6.35 to $6.65. Analysts polled by Capital IQ expect $6.41.
Net sales for the year are projected to be about $2.88 billion to about $2.91 billion, compared with a prior range of $2.87 billion to $2.90 billion. Analysts surveyed by Capital IQ expect $2.87 billion.
Price: 306.21, Change: +19.77, Percent Change: +6.90
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。